Psious develops a virtual reality platform designed to bring value to mental health treatment. The company's platform uses hyper-realistic virtual environments to treat anxiety disorders by means of virtual exposure therapy, enabling professionals to improve mental health therapies.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.
Koa Health is digital wellbeing and therapeutics solutions combine the latest clinical research and breakthrough technologies. It delivers mental health support that is accessible, personalized, and effective across a range of conditions.
They create digital tools and resources for mental health that encompass prevention, prediction, and treatment.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
Inbrain Neuroelectronics is a medical device company based in Barcelona, Spain, founded in 2019. The company focuses on developing and commercializing innovative graphene neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. By utilizing graphene technology, Inbrain creates high-density, full implantable platforms that can decode and modulate brain activity with precision. These advanced neural systems are designed to detect specific biomarkers related to therapies and to trigger targeted adaptive responses, thereby optimizing therapeutic outcomes for patients. Inbrain Neuroelectronics is dedicated to advancing the fields of neuro and bioelectronics through its cutting-edge solutions.
Anaconda Biomed SL, founded in 2015 and based in Barcelona, Spain, is focused on developing advanced healthcare devices, particularly in the field of neurology. The company specializes in creating catheters designed for mechanical thrombectomies, specifically targeting Acute Ischemic Stroke (AIS). Its flagship product, the ANCD BRAIN™, is a novel 3rd Generation Stented Aspiration Thrombectomy System that aims to improve treatment outcomes for patients experiencing AIS. Founded by Dr. Ofir Arad and Dr. Marc Ribó, Anaconda Biomed is recognized as an innovative player in the medical technology sector.
Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
Psious develops a virtual reality platform designed to bring value to mental health treatment. The company's platform uses hyper-realistic virtual environments to treat anxiety disorders by means of virtual exposure therapy, enabling professionals to improve mental health therapies.